SCHEMBL1782547

SCHEMBL1782547

COc1cc(B(O)OC(C)(C)C(C)(C)O)ccc1NC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.39
PIK3CD O00329 1/20 0.39
EGFR P00533 1/20 0.39
KDR P35968 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CG P48736 1/20 0.39
BACE1 P56817 1/20 0.39
PRKDC P78527 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
HTT P42858 2/20 0.39
PKM P14618 1/20 0.39
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
ABCB1 P08183 1/20 0.38
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NR1I2 O75469 1/20 0.36
KDM4E B2RXH2 1/20 0.36
PTK6 Q13882 1/20 0.36
EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL169631 0.85 HTT (0.44) ABL1PIK3CDEGFRKDRPIK3CA
SCHEMBL1991350 0.80 CYP17A1 (0.43)
SCHEMBL9893568 0.78 HDAC3 (0.42)
SCHEMBL19692162 0.78 CA2 (0.36) ALDH1A1TSHRCYP1A1CYP1A2
SCHEMBL473910 0.78 KDM4E (0.37) HTTALDH1A1GAANPSR1KDM4E
SCHEMBL6610808 0.77 CYP17A1 (0.49) PRKDC
SCHEMBL15457550 0.76 EPHX1 (0.57) ABL1PIK3CDEGFRKDRPIK3CA
SCHEMBL22336 0.75 MAOB (0.43) HTTALDH1A1TSHR
SCHEMBL2589170 0.75 ALDH1A1 (0.63) ALDH1A1GAATSHRNPSR1KDM4E
SCHEMBL26796625 0.75 ALDH1A1 (0.48) ABL1PIK3CDEGFRKDRPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118238-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118238-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS BUB1, BUB1B, TTBK1 ABL1 448/4885PIK3CD 749/4885EGFR 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.